Not for distribution to U.S. news wire services or dissemination in the United States. LONDON, Ontario, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Abitibi Metals Corp. (CSE: AMQ) (OTCQB: AMQFF) (FSE: FW0) (“Abitibi” or the “Company”) has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital Markets, as sole bookrunner, and Haywood Securities, as co-lead, under which the underwriters (the "Underwriters") have agreed to buy on bought deal basis 12,300,000 charity flo ...

The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial An independent Data Monitoring Committee (DMC) completed a safety review following adverse events identified in the BX004 Phase 2b trial and recommended that the study continue with revised dosing Following the DMC review, the study protocol will be updated, and topline results are now expe ...

Core Insights - Freddie Mac released its Monthly Volume Summary for October 2025, detailing its mortgage-related portfolios, securities issuance, risk management, delinquencies, debt activities, and other investments [1] Company Overview - Freddie Mac's mission is to enhance home accessibility for families nationwide, promoting liquidity, stability, and affordability in the housing market across various economic cycles [2] - Since its inception in 1970, Freddie Mac has assisted tens of millions of families in buying, renting, or maintaining their homes [2]

Core Viewpoint - Bright Minds Biosciences, Inc. is focused on developing highly selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and other CNS disorders, and is participating in key upcoming healthcare events [1][2]. Company Overview - Bright Minds Biosciences is a biotechnology company dedicated to creating innovative treatments for neurological and psychiatric disorders, with a pipeline that includes novel compounds targeting critical brain receptors [2]. - The company aims to address conditions with high unmet medical needs, including epilepsy and depression, by delivering breakthrough therapies that can significantly improve patients' lives [2]. Product Development - Bright Minds has developed a unique platform of highly selective serotonergic agonists that exhibit selectivity at various serotonergic receptors, resulting in a rich portfolio of new chemical entity (NCE) programs within neurology and psychiatry [3]. Upcoming Events - The company will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 11:30 am ET [1]. - Additionally, Bright Minds will be present at the 2025 American Epilepsy Society Annual Meeting during the Scientific Exhibit Session on December 7, 2025, from 2 pm to 5 pm ET [1].

Core Insights - BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapeutic products for metabolic diseases by targeting human aging biology [1][3] - The company will present at the Piper Sandler 37th Annual Healthcare Conference in New York from December 2-4, 2025 [1][2] - Key executives, including CEO Kristen Fortney and CFO Dov Goldstein, will participate in a fireside chat and one-on-one meetings during the conference [2] Company Overview - BioAge's lead product candidate, BGE-102, is an orally available small-molecule NLRP3 inhibitor aimed at treating obesity and cardiovascular risk factors [3] - A Phase 1 SAD/MAD trial for BGE-102 is currently underway, with initial SAD data expected by the end of the year [3] - The company is also developing long-acting injectable and oral small molecule APJ agonists for obesity, alongside additional preclinical programs targeting metabolic aging pathways [3]

Core Points - PhoneX Holdings, Inc. has appointed Vijay Ganapathy to the Board of Directors, effective November 20, 2025, succeeding Scott Tepfer who has resigned [1][2] - The company has adopted a Long-Term Cash Bonus Incentive Plan aimed at aligning employee incentives with long-term shareholder value creation [3][4] - The Plan allows for cash bonus payments contingent upon achieving measurable value-creation events, such as major corporate transactions and shareholder distributions [4][5] - Cash bonus awards under the Plan represent approximately 5% of Total Distributions at lower transaction thresholds, increasing to up to 15% for extraordinary outcomes [6] Company Overview - PhoneX Holdings, Inc. operates in the technology sector, focusing on the global wholesale trade of pre-owned mobile devices through its SaaS platform [7]

Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, British Columbia, Nov. 25, 2025 (GLOBE NEWSWIRE) -- South Pacific Metals Corp. (TSXV: SPMC) (FSE: 6J00) (“South Pacific Metals”, “SPMC” or the “Company”) is pleased to announce that it has entered into an agreement with a syndicate of agents led by BMO Capital Markets to market on a best-efforts basis by way of a private placement, up to C$8 million of units (the “Offering”) consisting of one common share and o ...

WEST PALM BEACH, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Onity Group Inc. (NYSE: ONIT) (“Onity” or the “Company”) today announced that Sean O’Neil, Executive Vice President and Chief Financial Officer with Onity Group, will present and host meetings with investors at the Bank of America Leveraged Finance Conference on December 2, 2025. Bank of America Leveraged Finance Conference Date: Tuesday, December 2, 2025Time: 3:30 p.m. to 4:00 p.m. Eastern Time This event will be webcast live through the link here. A ...

SUGAR LAND, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Applied Optoelectronics, Inc. (NASDAQ: AAOI) (“AOI”), a leading provider of advanced optical and HFC networking products that power the internet, today announced the Company will present via a fireside chat at the following investor conference: Event: Raymond James 2025 TMT & Consumer ConferenceDate: Tuesday, December 9th, 2025Presentation Time: 1:40 p.m. Eastern Time / 12:40 p.m. Central TimePresenter: Stefan Murry, Chief Financial Officer and Chief Stra ...

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: Piper Sandler 37th Annual Healthcare Conference, New York, NY Format – Fireside chat and 1x1 investor meetingsDate and Time – ...